<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM">
      <PMID Version="2">34244768</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1537-6613</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>224</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Sep</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of infectious diseases</Title>
          <ISOAbbreviation>J Infect Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model.</ArticleTitle>
        <Pagination>
          <StartPage>749</StartPage>
          <EndPage>753</EndPage>
          <MedlinePgn>749-753</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">jiab361</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1093/infdis/jiab361</ELocationID>
        <Abstract>
          <AbstractText>The emergence of SARS-CoV-2 variants of concern (VoCs) has exacerbated the COVID-19 pandemic. Currently available monoclonal antibodies and vaccines appear to have reduced efficacy against some of these VoCs. Antivirals targeting conserved proteins of SARS-CoV-2 are unlikely to be affected by mutations arising in VoCs and should therefore be effective against emerging variants. We here investigate the efficacy of molnupiravir, currently in phase 2 clinical trials, in hamsters infected with Wuhan strain or B.1.1.7 and B.1.351 variants. Molnupiravir proved to be effective against infections with each of the variants and therefore may have potential combating current and future emerging VoCs.</AbstractText>
          <CopyrightInformation>© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Abdelnabi</LastName>
            <ForeName>Rana</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Foo</LastName>
            <ForeName>Caroline S</ForeName>
            <Initials>CS</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>De Jonghe</LastName>
            <ForeName>Steven</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maes</LastName>
            <ForeName>Piet</ForeName>
            <Initials>P</Initials>
            <Identifier Source="ORCID">0000-0001-9118-8608</Identifier>
            <AffiliationInfo>
              <Affiliation>Laboratory of Clinical and Epidemiological Virology, Department of Microbiology, Immunology and Transplantation, Rega Institute, Katholieke Universiteit Leuven, Leuven, Belgium.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Zoonotic Infectious Diseases Unit, KU Leuven, Leuven, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Weynand</LastName>
            <ForeName>Birgit</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Imaging and Pathology, Division of Translational Cell and Tissue Research, Katholieke Universiteit Leuven, Leuven, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Neyts</LastName>
            <ForeName>Johan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Global Virus Network, Baltimore, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Infect Dis</MedlineTA>
        <NlmUniqueID>0413675</NlmUniqueID>
        <ISSNLinking>0022-1899</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006898">Hydroxylamines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5CSZ8459RP</RegistryNumber>
          <NameOfSubstance UI="D003562">Cytidine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YA84KI1VEW</RegistryNumber>
          <NameOfSubstance UI="C000656703">molnupiravir</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003562" MajorTopicYN="N">Cytidine</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006898" MajorTopicYN="N">Hydroxylamines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">B.1.351</Keyword>
        <Keyword MajorTopicYN="Y">SARS-CoV-2</Keyword>
        <Keyword MajorTopicYN="Y">VoC</Keyword>
        <Keyword MajorTopicYN="Y">antivirals</Keyword>
        <Keyword MajorTopicYN="Y">coronavirus</Keyword>
        <Keyword MajorTopicYN="Y">hamsters</Keyword>
        <Keyword MajorTopicYN="Y">molnupiravir</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>19</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34244768</ArticleId>
        <ArticleId IdType="pmc">PMC8408768</ArticleId>
        <ArticleId IdType="doi">10.1093/infdis/jiab361</ArticleId>
        <ArticleId IdType="pii">6318434</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Zhu N, Zhang D, Wang W, et al. . A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382:727–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7092803</ArticleId>
            <ArticleId IdType="pubmed">31978945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Plante JA, Mitchell BM, Plante KS, Debbink K, Weaver SC, Menachery VD. The variant gambit: COVID-19’s next move. Cell Host Microbe 2021; 29:508–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7919536</ArticleId>
            <ArticleId IdType="pubmed">33789086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabino EC, Buss LF, Carvalho MPS, et al. . Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. Lancet 2021; 397:452–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7906746</ArticleId>
            <ArticleId IdType="pubmed">33515491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wise J. Covid-19: the E484K mutation and the risks it poses. BMJ 2021; 372:n359.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33547053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Urakova N, Kuznetsova V, Crossman DK, et al. . β-d-N4-hydroxycytidine is a potent anti-alphavirus compound that induces a high level of mutations in the viral genome. J Virol 2017; 92:e01965-17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5774879</ArticleId>
            <ArticleId IdType="pubmed">29167335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toots M, Yoon JJ, Cox RM, et al. . Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med 2019; 11:eaax5866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6848974</ArticleId>
            <ArticleId IdType="pubmed">31645453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abdelnabi R, Foo CS, Kaptein SJF, et al. . The combined treatment of molnupiravir and favipiravir results in a marked potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model. bioRxiv, doi: 10.1101/2020.12.10.419242, 10.  March 2021, preprint: not peer reviewed. </Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/2020.12.10.419242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wahl A, Gralinski L, Johnson C, et al. . SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature 2021. doi:10.1038/s41586-021-03312-w</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-021-03312-w</ArticleId>
            <ArticleId IdType="pmc">PMC7979515</ArticleId>
            <ArticleId IdType="pubmed">33561864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cox RM, Wolf JD, Plemper RK. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nat Microbiol 2021; 6:11–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7755744</ArticleId>
            <ArticleId IdType="pubmed">33273742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Painter WP, Holman W, Bush JA, et al. . Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrob Agents Chemother 2021; 65:e02428-20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8092915</ArticleId>
            <ArticleId IdType="pubmed">33649113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Painter WP, Sheahan T, Baric R, et al. . Reduction in infectious SARS-CoV-2 in treatment study of COVID-19 with molnupiravir. Conference on Retroviruses and Opportunistic Infections, virtual, 6–10 March 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Abdelnabi R, Boudewijns R, Foo CS, et al. . Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters. EBioMedicine 2021; 68:103403. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8143995</ArticleId>
            <ArticleId IdType="pubmed">34049240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang P, Nair MS, Liu L, et al. . Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 2021; 593:130–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33684923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kupferschmidt K. New mutations raise specter of ‘immune escape’. Science 2021; 371:329–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33479129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hillen HS. Structure and function of SARS-CoV-2 polymerase. Curr Opin Virol 2021; 48:82–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8023233</ArticleId>
            <ArticleId IdType="pubmed">33945951</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
